Ipinzan

Metformin Hydrochloride and Vildagliptin, the active ingredient in Ipinzan, is a Biguanide; DPP‑4 inhibitor presented as an oral tablet for oral use. It treats type 2 diabetes mellitus in adults. GNH USA supplies Ipinzan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ipinzan is an oral antidiabetic medication used to improve glycaemic control in type 2 diabetes mellitus. - Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose when combined with diet and exercise. - Inadequate response to metformin alone: provides additional glucose‑lowering effect through DPP‑4 inhibition. - Patients requiring combination therapy: reduces HbA1c by targeting hepatic glucose production and incretin pathways.

Ipinzan may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhoea: watery stools, often transient. - Abdominal discomfort: cramping or bloating. - Headache: mild tension‑type headache. - Hypoglycaemia (when combined with sulfonylureas or insulin): symptomatic low blood sugar. - Metallic taste: transient alteration in taste perception.

Serious or Rare Side Effects: - Lactic acidosis: life‑threatening metabolic acidosis, especially in renal impairment. - Severe hypoglycaemia: prolonged low blood glucose requiring medical intervention. - Pancreatitis: acute inflammation of the pancreas. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or angio‑edema. - Stevens‑Johnson syndrome: severe skin reaction.

Before initiating Ipinzan, clinicians should consider several safety measures. - Renal function monitoring: assess creatinine clearance to avoid metformin accumulation. - Hepatic function assessment: evaluate liver enzymes due to risk of lactic acidosis. - Elderly patients: start at lower dose and monitor for adverse effects. - Metabolic acidosis risk: avoid in patients with conditions predisposing to acidosis. - Concomitant hypoglycaemic agents: adjust doses to prevent severe hypoglycaemia. - Store at room temperature: keep in the original container, protect from moisture and heat.

Ipinzan can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Renal impairment with contrast media: increased risk of metformin‑associated lactic acidosis. - Insulin or sulfonylureas: heightened risk of severe hypoglycaemia. - Cimetidine: may raise metformin plasma concentrations.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - Diuretics: can affect renal clearance of metformin. - ACE inhibitors or ARBs: monitor renal function and electrolytes.